<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-136057" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Fertility Preservation in Benign and Malignant Conditions</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Peterson</surname>
            <given-names>Andrea M.</given-names>
          </name>
          <aff>Medical University of South Carolina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Manvinder</given-names>
          </name>
          <aff>Montefiore/Einstein</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrea Peterson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manvinder Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-136057.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>As cancer survival rates improve in young men and women, fertility preservation becomes a topic that becomes relevant in malignant conditions. Additionally, several benign conditions may prompt women to consider their fertility preservation options, of which age-related fertility loss has gained popularity as more women choose to delay childbearing. Due to advances in assisted reproductive technologies, there are now a variety of methods to preserve fertility. This activity reviews the indications for fertility preservation in benign and malignant conditions and reviews fertility preservation techniques utilized by the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the benign conditions in women that may lead to the need for fertility preservation, and describe age-related fertility loss in women.</p></list-item><list-item><p>Identify the role of fertility preservation amongst transgender men and women.</p></list-item><list-item><p>Summarize the approach to fertility preservation in a patient with a new diagnosis of cancer and how cancer treatments may lead to a loss of fertility.</p></list-item><list-item><p>Describe fertility preservation techniques and indications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=136057&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=136057">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-136057.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>There are a variety of&#x000a0;benign and malignant indications for women that may cause a patient to seek fertility preservation counseling. Several benign conditions that may lead to early infertility include endometriosis, ovarian torsion, benign ovarian cysts, and&#x000a0;premature ovarian insufficiency, which may be a result of genetic conditions such as Turner syndrome, Fragile X premutation, or galactosemia.</p>
        <p>In addition, there are a variety of autoimmune medical&#x000a0;conditions such as Lupus Nephritis&#x000a0;and hematologic conditions such as sickle cell anemia and thalassemia that may require chemotherapy, radiotherapy, a combination of both chemotherapy and radiotherapy, and in some instances, even&#x000a0;bone marrow transplantation.<xref ref-type="bibr" rid="article-136057.r1">[1]</xref><xref ref-type="bibr" rid="article-136057.r2">[2]</xref>&#x000a0;These interventions for benign medical conditions&#x000a0;may result in an&#x000a0;early loss of fertility. Surgeries in the pelvis may also&#x000a0;diminish a women's ovarian reserve and lead to issues with fertility.<xref ref-type="bibr" rid="article-136057.r3">[3]</xref><xref ref-type="bibr" rid="article-136057.r4">[4]</xref></p>
      </sec>
      <sec id="article-136057.s3" sec-type="Function">
        <title>Function</title>
        <p>There has been a trend over the past half-century of delaying motherhood. There is known to be age-related fertility loss for women, and thus with the delay in childbearing more women are now seeking oocyte cryopreservation and other fertility preservation techniques to have children at a later date.<xref ref-type="bibr" rid="article-136057.r5">[5]</xref></p>
        <p>Another group to consider is the newly emerging population of transgender individuals at risk of infertility after pursuing gender-affirming surgeries or hormone therapy. The options for transgender preservation of fertility depend on the specific phase of&#x000a0;transgender transition that the patient is undergoing. For transgender women, who were assigned male at birth, options before gender transition with hormones or surgery include cryopreservation of sperm or testicular tissue.<xref ref-type="bibr" rid="article-136057.r6">[6]</xref>&#x000a0;</p>
        <p>If puberty has already occurred, the patient may obtain semen from ejaculation or testicular sperm extraction (TESE). If TESE specimens are used, the sperm collected may only be used for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), whereas if ejaculated sperm is used, it may be used for intrauterine inseminations (IUI)&#x000a0;as well as IVF or ICSI. For prepubertal transgender girls&#x000a0;who have not started gender-affirming hormones, the only option for fertility preservation is testicular tissue cryopreservation.<xref ref-type="bibr" rid="article-136057.r6">[6]</xref>&#x000a0;</p>
        <p>If a transgender woman has started hormone therapy with estrogen, the suppression of spermatogenesis is reversible after holding therapy for at least three months.<xref ref-type="bibr" rid="article-136057.r7">[7]</xref>&#x000a0;Thus they may discontinue estrogen treatment and cryopreserve sperm. If a transgender woman has undergone genital reconstruction, there are no options to reverse sterility.</p>
        <p>On the other hand, options for fertility preservation in&#x000a0;transgender men,&#x000a0;who were assigned female at birth, include oocyte and embryo cryopreservation or ovarian tissue cryopreservation if they present before receiving&#x000a0;hormone therapy or surgery. For these patients, controlled ovarian stimulation is used to obtain eggs for oocyte and embryo cryopreservation. If a transgender male has already started hormone therapy with testosterone studies, have recommended cessation of testosterone for at least three months.<xref ref-type="bibr" rid="article-136057.r8">[8]</xref>&#x000a0;There are a couple of case reports that demonstrate successful&#x000a0;ovarian stimulation without testosterone cessation; however, until further&#x000a0;larger studies are performed, the recommended practice at this time is for testosterone cessation.<xref ref-type="bibr" rid="article-136057.r9">[9]</xref><xref ref-type="bibr" rid="article-136057.r10">[10]</xref>&#x000a0;</p>
        <p>A strategy to reduce the estrogenic symptoms from ovarian stimulation for this group is to use an antagonist protocol with the addition of letrozole.<xref ref-type="bibr" rid="article-136057.r11">[11]</xref>&#x000a0;Cryopreservation of ovarian tissue for these patients may be ideally performed at the time of gender-affirmation surgery and is the only option for prepubertal transgender boys.<xref ref-type="bibr" rid="article-136057.r6">[6]</xref>&#x000a0;This cryopreserved tissue may then be used at a later time for either reimplantation or to obtain immature oocytes and attempt in vitro maturation (IVM).</p>
      </sec>
      <sec id="article-136057.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Malignant conditions are also a very common indication for an individual to seek fertility preservation. With improvements in cancer treatment, there has been a decrease in mortality, leading to a growing group of young woman survivors who wish to have children.<xref ref-type="bibr" rid="article-136057.r2">[2]</xref>&#x000a0;</p>
        <p>There are different&#x000a0;degrees of damage to the ovaries based on the type of cancer treatment administered. The degree of gonadotoxicity depends on several factors, including the ovarian reserve when starting treatment, the patient's age at the time of treatment, the specific type of chemotherapy and or radiotherapy, and the duration and dose of the cancer treatment.<xref ref-type="bibr" rid="article-136057.r12">[12]</xref>&#x000a0;</p>
        <p>If a patient is older and has a lower anti-mullerian hormone level before starting a toxic cancer treatment, they will have increased risks of infertility&#x000a0;<xref ref-type="bibr" rid="article-136057.r4">[4]</xref>. Thus due&#x000a0;to the wide range of effects, patients should be counseled on fertility preservation options in an individualized manner.</p>
        <p>Patients who receive a new diagnosis of malignancy should be rapidly referred to a fertility specialist to receive fertility preservation counseling.<xref ref-type="bibr" rid="article-136057.r13">[13]</xref>&#x000a0;There should also be a multidisciplinary approach to treating newly diagnosed cancer patients with a team of oncologists, reproductive endocrinologists and surgeons, urologists, mental health professionals, and genetic counselors. It is also important to consider the patient's current health status as if a patient is too ill; they may not be a candidate to receive fertility preservation therapy. For patients that may be receiving pelvic radiation, the option of using a gestational carrier should be discussed.<xref ref-type="bibr" rid="article-136057.r14">[14]</xref>&#x000a0;</p>
        <p>Another option that is specific to women who will receive pelvic radiation is an ovarian transposition, where the ovaries are mobilized and affixed to a location in the abdomen free of radiation.<xref ref-type="bibr" rid="article-136057.r15">[15]</xref>&#x000a0;It is important to note that if a patient has ovarian transposition, it may prohibit future transvaginal oocyte retrieval and require a transabdominal approach.&#x000a0;</p>
      </sec>
      <sec id="article-136057.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>For postpubertal women who receive a new diagnosis of malignancy, their fertility preservation options include controlled ovarian stimulation with embryo or oocyte cryopreservation. Embryo cryopreservation may offer a prognosis on a live birth rate based on the patient's age, along with the number and quality of embryos with or without preimplantation genetic test results. Oocyte cryopreservation may be the preferred method if a patient does not have a committed male partner or does not wish to use donor sperm. Predictors for success with the use of mature oocytes include the age of the patient at vitrification and the number of oocytes cryopreserved.<xref ref-type="bibr" rid="article-136057.r16">[16]</xref></p>
        <p>Women with a cancer diagnosis who desire future fertility should immediately undergo controlled ovarian stimulation with a gonadotropin-releasing hormone (GnRH) antagonist protocol regardless of the phase of the menstrual cycle to prevent a delay in treatment.<xref ref-type="bibr" rid="article-136057.r17">[17]</xref>&#x000a0;As the women may often be young, they should be triggered with a GnRH agonist&#x000a0;for final oocyte maturation before retrieval to prevent the risk of ovarian hyperstimulation syndrome.<xref ref-type="bibr" rid="article-136057.r18">[18]</xref>&#x000a0;Additionally, to prevent venous thromboembolism and hyperestrogenemia in estrogen-sensitive cancers, letrozole or tamoxifen may be used during stimulation.<xref ref-type="bibr" rid="article-136057.r19">[19]</xref>&#x000a0;</p>
        <p>It is also recommended to cryopreserve the gametes before initiation of cancer therapy as there have not been any human studies examining the quality of embryos and oocytes following treatment with chemotherapy.<xref ref-type="bibr" rid="article-136057.r13">[13]</xref>&#x000a0;The use of GnRH analogs for ovarian protection during chemotherapy remains controversial and should not be used as an alternative to fertility preservation treatment.<xref ref-type="bibr" rid="article-136057.r20">[20]</xref>&#x000a0;</p>
        <p>In prepubertal girls with a new cancer diagnosis, the only option for fertility preservation is ovarian tissue cryopreservation, which is no longer considered experimental.<xref ref-type="bibr" rid="article-136057.r13">[13]</xref>&#x000a0;Ovarian tissue cryopreservation is also an option for women who cannot delay the start of cancer therapy to undergo ovarian stimulation with subsequent oocyte retrieval. Ovarian tissue cryopreservation involves removing ovarian cortical tissue and freezing it for future transplantation. Orthotopic transplantation, where the cryopreserved tissue is transplanted to a location within the pelvis, is a more successful method in humans than heterotopic transplant, where the cryopreserved tissue is transplanted to an area outside the pelvis such as the upper extremity. If there is a possibility that cancer cells are present in cryopreserved ovarian tissue, autologous transplantation is contraindicated due to the risk of reseeding cancer.<xref ref-type="bibr" rid="article-136057.r21">[21]</xref>&#x000a0;</p>
        <p>Additionally, if a patient underwent a bilateral salpingo-oophorectomy due to being a carrier of a BRCA mutation, it is not recommended that they have ovarian tissue transplantation given the increased possibility of having ovarian cancer.<xref ref-type="bibr" rid="article-136057.r13">[13]</xref>&#x000a0;Another option a BRCA carrier patient or a patient with limited time before receiving a gonadotoxic cancer treatment may consider is IVM, which is no longer considered experimental.<xref ref-type="bibr" rid="article-136057.r22">[22]</xref>&#x000a0;IVM is the process in which immature oocytes in the germinal vesicle or metaphase I stage are matured in the laboratory setting.&#x000a0;Patients considering in vitro maturation should be counseled that there is a lower associated pregnancy rate compared to conventional IVF.<xref ref-type="bibr" rid="article-136057.r22">[22]</xref></p>
      </sec>
      <sec id="article-136057.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>Fertility preservation options specific to postpubertal men with a new cancer diagnosis include sperm cryopreservation before initiation of chemotherapy. Preferably two to three samples should be obtained.&#x000a0;A male may be&#x000a0;unable to ejaculate via masturbation for various reasons, including pubertal status, anxiety, hypogonadism, medications such as antidepressants and opioids, medical comorbidities such as diabetes, or neurologic issues, and underlying cancer.<xref ref-type="bibr" rid="article-136057.r13">[13]</xref>&#x000a0;</p>
        <p>In these circumstances, phosphodiesterase type 5 inhibitors, which are typically used to treat erectile dysfunction, may be used to help obtain a semen sample if there are no contraindications.<xref ref-type="bibr" rid="article-136057.r23">[23]</xref>&#x000a0;Additionally, penile vibratory stimulation can be used, which helps to trigger the ejaculatory reflex in a noninvasive manner. If penile vibratory stimulation fails, electroejaculation is another option that uses a transrectal probe and is typically performed with anesthetics.<xref ref-type="bibr" rid="article-136057.r24">[24]</xref>&#x000a0;</p>
        <p>Men may also experience retrograde ejaculation if they have diabetes, take&#x000a0;antidepressant and antipsychotic medications, or have had prior surgery to the prostate or a retroperitoneal lymph node dissection. First-line treatment in these patients is the use of an alpha-agonist to restore antegrade ejaculation by tightening the muscles at the bladder neck and preventing semen from traveling into the bladder. If men have contraindications or fail to respond to alpha-agonists, another option is to alkalinize and collect the urine for processing viable sperm.<xref ref-type="bibr" rid="article-136057.r25">[25]</xref>&#x000a0;</p>
        <p>Additionally, there is the option for TESE with subsequent IVF or ICSI, as mentioned previously. In prepubertal boys, testicular tissue cryopreservation is still considered experimental and must be performed in the setting of a clinical trial.</p>
      </sec>
      <sec id="article-136057.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interdisciplinary teamwork is important with fertility preservation. In cases where a patient is diagnosed with cancer, collaboration&#x000a0;amongst&#x000a0;the oncologist and reproductive specialists&#x000a0;is key. The American Society of Clinical Oncology released&#x000a0;an updated guideline in 2013 stating that oncologists should address the possibility of infertility with their patients before cancer therapy is initiated and should refer the patient to reproductive endocrinologists.<xref ref-type="bibr" rid="article-136057.r26">[26]</xref>&#x000a0;[Level 2]&#x000a0;</p>
        <p>In cases of elective fertility preservation, the reproductive endocrinologist needs to collaborate with the primary care physician. It is also important for the financial department to determine the funding for the patient through insurance or organizations that donate to patients with a diagnosis of cancer.</p>
      </sec>
      <sec id="article-136057.s8">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=136057&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=136057">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/136057/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=136057">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-136057.s9">
        <title>References</title>
        <ref id="article-136057.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sleiman</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Karaman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Terzic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Terzic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falzone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Garzon</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Fertility Preservation in Benign Gynecological Diseases: Current Approaches and Future Perspectives.</article-title>
            <source>J Reprod Infertil</source>
            <year>2019</year>
            <season>Oct-Dec</season>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>201</fpage>
            <page-range>201-208</page-range>
            <pub-id pub-id-type="pmid">31897386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolmans</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Manavella</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in fertility preservation.</article-title>
            <source>J Obstet Gynaecol Res</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>266</fpage>
            <page-range>266-279</page-range>
            <pub-id pub-id-type="pmid">30246274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raffi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Metwally</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Amer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>3146</fpage>
            <page-range>3146-54</page-range>
            <pub-id pub-id-type="pmid">22723324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>ESHRE Guideline Group on Female Fertility Preservation</collab>
              <name>
                <surname>Anderson</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Amant</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Braat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chuva de Sousa Lopes</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Demeestere</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dwek</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frith</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lambertini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maslin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Moura-Ramos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nogueira</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rodriguez-Wallberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>ESHRE guideline: female fertility preservation.</article-title>
            <source>Hum Reprod Open</source>
            <year>2020</year>
            <volume>2020</volume>
            <issue>4</issue>
            <fpage>hoaa052</fpage>
            <pub-id pub-id-type="pmid">33225079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fritz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jindal</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reproductive aging and elective fertility preservation.</article-title>
            <source>J Ovarian Res</source>
            <year>2018</year>
            <month>Aug</month>
            <day>11</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <pub-id pub-id-type="pmid">30098598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ainsworth</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Allyse</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Fertility Preservation for Transgender Individuals: A Review.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>95</volume>
            <issue>4</issue>
            <fpage>784</fpage>
            <page-range>784-792</page-range>
            <pub-id pub-id-type="pmid">32115195</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Swerdloff</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Christenson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Handelsman</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <collab>Hormonal Male Contraception Summit Group</collab>
            </person-group>
            <article-title>Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.</article-title>
            <source>Lancet</source>
            <year>2006</year>
            <month>Apr</month>
            <day>29</day>
            <volume>367</volume>
            <issue>9520</issue>
            <fpage>1412</fpage>
            <page-range>1412-20</page-range>
            <pub-id pub-id-type="pmid">16650651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Roo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tilleman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>T'Sjoen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Sutter</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Fertility options in transgender people.</article-title>
            <source>Int Rev Psychiatry</source>
            <year>2016</year>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>112</fpage>
            <page-range>112-9</page-range>
            <pub-id pub-id-type="pmid">26835612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gale</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Magee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Forsyth-Greig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Visram</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oocyte cryopreservation in a transgender man on long-term testosterone therapy: a case report.</article-title>
            <source>F S Rep</source>
            <year>2021</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-251</page-range>
            <pub-id pub-id-type="pmid">34278362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cho</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harjee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Fertility preservation in a transgender man without prolonged discontinuation of testosterone: a case report and literature review.</article-title>
            <source>F S Rep</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-47</page-range>
            <pub-id pub-id-type="pmid">34223211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armuand</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dhejne</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Olofsson</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Rodriguez-Wallberg</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Transgender men's experiences of fertility preservation: a qualitative study.</article-title>
            <source>Hum Reprod</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>383</fpage>
            <page-range>383-390</page-range>
            <pub-id pub-id-type="pmid">27999119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donnez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dolmans</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Fertility Preservation in Women.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Oct</month>
            <day>26</day>
            <volume>377</volume>
            <issue>17</issue>
            <fpage>1657</fpage>
            <page-range>1657-1665</page-range>
            <pub-id pub-id-type="pmid">29069558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <collab>Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org</collab>
            <article-title>Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion.</article-title>
            <source>Fertil Steril</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>1022</fpage>
            <page-range>1022-1033</page-range>
            <pub-id pub-id-type="pmid">31843073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Signorello</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Mulvihill</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Munro</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Stovall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weathers</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Whitton</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Robison</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Boice</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>Aug</month>
            <day>21</day>
            <volume>376</volume>
            <issue>9741</issue>
            <fpage>624</fpage>
            <page-range>624-30</page-range>
            <pub-id pub-id-type="pmid">20655585</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costa-Roig</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Andr&#x000e9;s Moreno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bordallo V&#x000e1;zquez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cort&#x000e9;s S&#x000e1;ez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Del Peral Samaniego</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Chac&#x000f3;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marco-Maci&#x000e1;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vila Carb&#x000f3;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ovarian transposition as a minimally invasive fertility preservation technique: ten years of experience in a pediatric center.</article-title>
            <source>Cir Pediatr</source>
            <year>2020</year>
            <month>Jan</month>
            <day>20</day>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-29</page-range>
            <pub-id pub-id-type="pmid">32166920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cobo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Velasco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Domingo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pellicer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Remoh&#x000ed;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Elective and Onco-fertility preservation: factors related to IVF outcomes.</article-title>
            <source>Hum Reprod</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>2222</fpage>
            <page-range>2222-2231</page-range>
            <pub-id pub-id-type="pmid">30383235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cakmak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Random-start ovarian stimulation in patients with cancer.</article-title>
            <source>Curr Opin Obstet Gynecol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-21</page-range>
            <pub-id pub-id-type="pmid">25919235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <collab>Practice Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org</collab>
            <collab>Practice Committee of the American Society for Reproductive Medicine</collab>
            <article-title>Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline.</article-title>
            <source>Fertil Steril</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>106</volume>
            <issue>7</issue>
            <fpage>1634</fpage>
            <page-range>1634-1647</page-range>
            <pub-id pub-id-type="pmid">27678032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Oktay</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Safety of Letrozole and Gonadotropin Stimulation for Fertility Preservation in Women With Breast Cancer.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>1364</fpage>
            <page-range>1364-71</page-range>
            <pub-id pub-id-type="pmid">26751194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oktay</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Partridge</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Reinecke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Loren</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update.</article-title>
            <source>J Clin Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>36</volume>
            <issue>19</issue>
            <fpage>1994</fpage>
            <page-range>1994-2001</page-range>
            <pub-id pub-id-type="pmid">29620997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dolmans</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Marinescu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Saussoy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Langendonckt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amorim</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Donnez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe.</article-title>
            <source>Blood</source>
            <year>2010</year>
            <month>Oct</month>
            <day>21</day>
            <volume>116</volume>
            <issue>16</issue>
            <fpage>2908</fpage>
            <page-range>2908-14</page-range>
            <pub-id pub-id-type="pmid">20595517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <collab>Practice Committees of the American Society for Reproductive Medicine, the Society of Reproductive Biologists and Technologists, and the Society for Assisted Reproductive Technology. Electronic address: jgoldstein@asrm.org</collab>
            <article-title>In&#x000a0;vitro maturation: a committee opinion.</article-title>
            <source>Fertil Steril</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>298</fpage>
            <page-range>298-304</page-range>
            <pub-id pub-id-type="pmid">33358333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tur-Kaspa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moffa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Massobrio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Viagra for temporary erectile dysfunction during treatments with assisted reproductive technologies.</article-title>
            <source>Hum Reprod</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>7</issue>
            <fpage>1783</fpage>
            <page-range>1783-4</page-range>
            <pub-id pub-id-type="pmid">10402389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Fan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Electroejaculation combined with assisted reproductive technology in psychogenic anejaculation patients refractory to penile vibratory stimulation.</article-title>
            <source>Transl Androl Urol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>Suppl 1</issue>
            <fpage>S17</fpage>
            <page-range>S17-S22</page-range>
            <pub-id pub-id-type="pmid">29644166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohl</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Quallich</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>S&#x000f8;nksen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brackett</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Lynne</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Anejaculation and retrograde ejaculation.</article-title>
            <source>Urol Clin North Am</source>
            <year>2008</year>
            <month>May</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-20, viii</page-range>
            <pub-id pub-id-type="pmid">18423241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-136057.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Loren</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Mangu</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Magdalinski</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Partridge</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Oktay</surname>
                <given-names>K</given-names>
              </name>
              <collab>American Society of Clinical Oncology</collab>
            </person-group>
            <article-title>Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.</article-title>
            <source>J Clin Oncol</source>
            <year>2013</year>
            <month>Jul</month>
            <day>01</day>
            <volume>31</volume>
            <issue>19</issue>
            <fpage>2500</fpage>
            <page-range>2500-10</page-range>
            <pub-id pub-id-type="pmid">23715580</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
